Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Let the bidding begin

This article was originally published in The Gray Sheet

Executive Summary

First round of Medicare competitive bidding for durable medical equipment opens May 15. Suppliers of devices in 10 product categories (including wheelchairs, oxygen equipment and respiratory assist devices) in the 10 metropolitan areas outlined in CMS' April 2 final rule have until July 13 to submit bids and until Aug. 31 to gain supplier accreditation. Winning bidders will be selected in December to participate in the program starting April 1, 2008 (1"The Gray Sheet" April 9, 2007, p. 3)...

You may also be interested in...



Final Regulation Establishes Competitive Bidding For Durable Equipment

CMS will require certain medical supply manufacturers to begin submitting pricing bids to Medicare this month under a final 1regulation published April 2

Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules. 

Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff

Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024822

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel